Loading…
Wednesday September 30, 2026 10:15 - 11:00 CEST
Amyotrophic Lateral Sclerosis (ALS) poses major scientific, clinical, and societal challenges. At the same time, unprecedented advances in molecular biology, drug discovery, biomarkers, precision medicine, and advanced therapeutic approaches are transforming the landscape of neurological research and care.

This round table will bring together leading experts from academia, biotechnology, and clinical practice to discuss the latest innovations driving the development of next-generation therapies for ALS. The discussion will explore emerging therapeutic strategies, including novel small molecules, biologics, regenerative and gene-based approaches, as well as the critical role of translational research in accelerating their path to patients.

Participants will examine how cutting-edge discoveries are being validated through clinical studies and real-world evidence, addressing key challenges related to efficacy assessment, biomarker development, patient stratification, regulatory pathways, and long-term outcomes. Particular attention will be paid to cross-disciplinary collaboration and innovation. The session will provide a comprehensive perspective on how scientific breakthroughs are advancing from the laboratory to clinical validation and, ultimately, to improved patient outcomes.

Key themes:
  • Advanced therapeutic approaches for ALS
  • Translational pathways from discovery to clinical application
  • Biomarkers and patient stratification for precision neurology
  • Clinical trial innovation and real-world evidence generation
  • Collaboration between academia, healthcare systems, and biotech companies
  • Future opportunities and challenges in neurodegenerative disease treatment development
This discussion will offer attendees a unique opportunity to gain insights into the evolving neurodegenerative disease ecosystem and the strategies shaping the next generation of therapeutic innovation.


Moderators
MS

Maite Solas

Vice-president, FUNDELA

Speakers
avatar for Manuel Cuervas-Mons Cantón

Manuel Cuervas-Mons Cantón

Medical Lead Innovative Medicines, Bristol Myers Squibb (BSM)
Medical Doctor, PhD, and board-certified surgeon with over 10 years of clinical experience in a tertiary hospital, where I led complex surgical cases and coordinated the Foot & Ankle Unit.

Driven by the ambition to improve patient outcomes beyond the operating room, I transitioned

... Read More →
avatar for Yosu Vara

Yosu Vara

Chemistry and Manufacturing Director, cofounder, Quimatriyx
He has 20 years of experience in the biotechnology and pharmaceutical industry, where he has managed drug discovery projects. He is the author of more than 20 patents and publications in organic chemistry.
He holds a PhD in Organic Chemistry from the University of the Basque Count... Read More →
avatar for Adolfo López de Munain

Adolfo López de Munain

Miramoon Pharma & SEED-ALS coordinator/leader, Osakidetza, IIS Biogipuzkoa, Miramoon Pharma
Dr. López de Munain is Chief Scientific Officer and Co-Founder of MiramoonPharma, with over 35 years of experience in clinical neurology, neurogenetics,and translational neuroscience. He holds an MD and a PhD in Medicine from theUniversity of Navarra, where he conducted his doctoral... Read More →
avatar for Ana Martínez Gil

Ana Martínez Gil

Cofounder & Scientific Advisory Board Member, Molefy Pharma
Experta en descubrimiento de fármacos y química medicinal, con más de 25 años de experiencia en enfermedades neurodegenerativas. Es profesora de investigación en el CIB-CSIC y cofundadora de Molefy Pharma.
Wednesday September 30, 2026 10:15 - 11:00 CEST
2 Dorotea Barnés room

Sign up or log in to save this to your schedule, view media, leave feedback and see who's attending!

Share Modal

Share this link via

Or copy link